Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 18/20 | 0.56 |
| ▸ | UBA3 | Q8TBC4 | 16/20 | 0.56 |
| ▸ | UBA1 | P22314 | 1/20 | 0.49 |
| ▸ | UBA6 | A0AVT1 | 2/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | GRK5 | P34947 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353882 | 0.89 | NAE1 (0.71) | NAE1UBA3UBA1UBA6SAE1 | |
| SCHEMBL783631 | 0.89 | NAE1 (0.71) | NAE1UBA3UBA1UBA6SAE1 | |
| SCHEMBL10283696 | 0.82 | NAE1 (0.53) | NAE1UBA3UBA1UBA6SAE1 | |
| SCHEMBL192881 | 0.78 | NAE1 (0.73) | NAE1UBA3UBA1UBA6SAE1 | |
| SCHEMBL192956 | 0.78 | NAE1 (0.73) | NAE1UBA3UBA1UBA6SAE1 | |
| SCHEMBL17875191 | 0.78 | NAE1 (0.73) | NAE1UBA3UBA1UBA6SAE1 | |
| SCHEMBL192416 | 0.78 | NAE1 (0.73) | NAE1UBA3UBA1UBA6SAE1 | |
| SCHEMBL782894 | 0.78 | NAE1 (0.60) | NAE1UBA3UBA1 | |
| SCHEMBL12392908 | 0.78 | NAE1 (0.53) | NAE1UBA3UBA1UBA6SAE1 | |
| SCHEMBL782861 | 0.78 | NAE1 (0.53) | NAE1UBA3UBA1UBA6SAE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | NAE1 24/4885UBA3 6/4885UBA1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.